Oric Pharmaceuticals (ORIC) Interest Expenses (2019 - 2026)

Oric Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $99.6 million for Q1 2026.

• Quarterly Interest Expenses rose 748.53% year-over-year to $99.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.6 million (up 748.53% YoY) and the FY2025 annual result came in at $212.6 million, up 23.2% from the prior year.
• Interest Expenses was $99.6 million for Q1 2026 at Oric Pharmaceuticals, up from $80.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $172.6 million in Q4 2024 and bottomed at $154000.0 in Q4 2022.
• A 5-year average of $49.2 million and a median of $26.3 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses tumbled 95.21% — and 2023, when it surged 86240.91%.
• Oric Pharmaceuticals' Interest Expenses stood at $154000.0 in 2022, then jumped by 86240.91% to $133.0 million in 2023, then increased by 29.78% to $172.6 million in 2024, then tumbled by 53.47% to $80.3 million in 2025, then gained by 24.04% to $99.6 million in 2026.
• Business Quant data shows ORIC's Interest Expenses at $99.6 million in Q1 2026, $80.3 million in Q3 2025, and $56.4 million in Q2 2025.